TROP2-ADC for advanced neuroendocrine tumors after standard therapy
Part of Cancer clinical trials.
This trial tests a medicine called TROP2-ADC, which targets a protein on cancer cells to kill them. It is for people with advanced high-grade neuroendocrine tumors that have not responded to standard treatments. The goal is to see if this drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a high-grade neuroendocrine tumor (NEC, NET G3, or mixed tumor with >30% neuroendocrine cells) that has spread to other parts of the body.
- At least one standard treatment has stopped working (your cancer has grown despite therapy).
- You are able to take care of yourself (ECOG performance status 0 or 1) and doctors expect you to live at least 3 more months.
- You have a tumor that can be measured on a scan, and your major organs (bone marrow, liver, kidneys) are working well enough.
- You are not pregnant, and you agree to use effective birth control during and for 3 months after treatment. You cannot have active brain metastases or severe lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial uses a special PET scan to find a protein called Trop-2 on your cancer cells. It helps doctors decide if a targeted treatment (Trop-2 ADC) might work for you.
This early-phase study tests an antibody-drug (an ADC) that targets TROP2, given by itself and together with an anti–PD-1 medicine. It’s for people with advanced solid cancers that have not responded to standard treatments, aiming to shrink tumors and improve control of the disease.
This trial tests a new treatment called Trop2 CAR-NK, which uses your own immune cells modified to attack lung cancer cells that have a protein called Trop2. It is for people with advanced non-small cell lung cancer that has not responded to standard therapies.
This trial uses a special PET scan to see if a type of drug called Trop2-ADC is working in people with advanced breast cancer. The scan may help doctors decide if the treatment is right for you.
This trial tests a new imaging scan (two types of PET/CT) to see how well it tracks tumor response to a TROP2-targeted drug in people with EGFR-mutant lung cancer that stopped responding to standard pills. It aims to improve how doctors measure treatment success.
Hear when a new Neuroendocrine Neoplasms (Tumours) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.